SMi is proud to present their 6th annual Cancer Vaccines conference, due to be held in London in September 2017. Combination therapies remain the most effective cancer treatment available. Diversification of cancer vaccines has propelled growth and innovation within the industry over the past year; and developments in the enhancement of efficacy of treatments are becoming ever more prevalent.

With focal points of the conference including autologous tumour cell immunotherapy, combinatorial approaches (including immune checkpoint inhibitors and IDO inhibitors) and case studies of current clinical trials, this conference will provide the perfect platform to highlight emerging strategies in cancer vaccines. The conference will also aim to provide solutions to circumvent the challenges which face the development of successful targeted cancer treatments, within a competitive and important market.

This event will bring together integral personalities from within the field - from key academics at the forefront of research, to industry leaders, in order to collaborate and network. The 16+ industry led presentations and focus on the latest advances in personalised cancer treatments make this a leading event for the cancer vaccines industry.

• An industry led event featuring numerous high level and instructive case studies on the techniques for developing personalised cancer vaccines, characterizing and applying the outside-in approach in cancer vaccine development
• High number of innovative talks on novel approaches from biotech speakers
• Focus on associated therapies; CAR T cell therapies and combination therapies including immune checkpoint inhibitors and IDO inhibitors, maximising the therapeutic potential
• Emerging and novel therapies will be highlighted, including in depth case study examples showcasing peptide, neoantigen and MHC based vaccine development

Agnete B. Fredriksen is Founder and Chief Scientific Officer of Vaccibody AS. She holds a M.Sc., Ph.D. from Institute of Immunology, University of Oslo, Rikshospitalet in Norway where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies. She has co-authored a range of scientific papers and is inventor on several patents with a focus on vaccine development and immunotherapy. She is in charge of preclinical and clinical development of Vaccibody’s cancer vaccine programs.

Farzin joined King’s College London as a lecturer in Molecular Genetics in 1985, founded the Molecular Genetics Unit in 1986 and was appointed the founding Head of the Department of Molecular Genetics in 1993. Farzin has published over 200 scientific papers and two edited books on the Functional Analysis of the Genome and Cancer Gene Therapy. He leads an active research group with a current funding of over £2M per annum from Leukaemia Lymphoma Research (now Bloodwise), CRUK, National Institute for Health Research, UK Research Councils, as well as the biotech and pharmaceutical industry.

10:30 Morning Coffee

Dr. Kandeepan Ganeshalingam received his Medical Degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine, University of London. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK.
Following a 10 year career as a physician in the National Health Service Hospitals, UK, he joined the Oncology product development team at Roche in 2007. In this role he played a significant role in product development with several successful submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the Global Head of Medical and Clinical Drug Safety, where he played a leadership role in clinical development, regulatory submissions and safety risk management. In 2012, he returned to Roche Product Development Medical Affairs as Senior Medical Director, in immunology and was subsequently promoted to Group Medical Director in Oncology, where he led the Global Medical team responsible for multiple Haematology/Oncology products. In this role he was instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies.
In 2016, he joined Merck Sharp Dohme as the Executive Director, Oncology Therapeutic Area Head, European Clinical Development.

11:40 Activation of the immune system in combination with checkpoint inhibitors

Dr. Giljohann has served as Exicure’s Chief Executive Officer since November 2013 and been on its board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was Exicure’s Chief Operating Officer and its founding scientist in 2011. From 2011 to June 2012, Dr. Giljohann served as the company’s principal scientist. Prior to that, Dr. Giljohann was the founding scientist of AuraSense, LLC in 2009. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.

12:20 Networking Lunch

13:30 Combining RNAi and immune oncology

Amotz Shemi, CEO, Silenseed

14:10 Vaccines with phosphopeptides

Zahra Jawad, Group Leader in Discovery Technology, Agenus

• Phosphopeptides as an alternative to peptides for vaccinations
• New data showing the immunogenicity profile of phosphopeptides
• Pre-clinical models of anti-tumour efficacy

17:30 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Alfredo is CEO of Nouscom AG, a biotech company dedicated to the development of next generation immunotherapies to beat cancer (www.nouscom.com).
Alfredo is also CEO of Reithera srl, a Biotech involved in the development of vector-based anti-infectious vaccines.
Alfredo is full Professor of Molecular Biology at the University Federico II, Naples (Italy).
Alfredo was a co-founder of Okairos (recently acquired by GSK) and served as the company’s Chief Scientific Officer, contributing to the preclinical and clinical development of a number of vaccines and monoclonal antibodies against infectious diseases and cancer.
Alfredo’s experience includes the positions of senior director of the Viral Diseases Vaccine program at Istituto di Ricerche di Biologia Molecolare (IRBM), staff scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and project leader at the Sclavo Research Centre in Siena, Italy.
He has also published over 150 articles in leading journals on a range of subjects, including viral and bacterial infection and vaccines and holds a number of patents and patent applications.
Alfredo holds a degree in chemistry from the University of Rome, Italy.

Alfredo is CEO of Nouscom AG, a biotech company dedicated to the development of next generation immunotherapies to beat cancer (www.nouscom.com).
Alfredo is also CEO of Reithera srl, a Biotech involved in the development of vector-based anti-infectious vaccines.
Alfredo is full Professor of Molecular Biology at the University Federico II, Naples (Italy).
Alfredo was a co-founder of Okairos (recently acquired by GSK) and served as the company’s Chief Scientific Officer, contributing to the preclinical and clinical development of a number of vaccines and monoclonal antibodies against infectious diseases and cancer.
Alfredo’s experience includes the positions of senior director of the Viral Diseases Vaccine program at Istituto di Ricerche di Biologia Molecolare (IRBM), staff scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and project leader at the Sclavo Research Centre in Siena, Italy.
He has also published over 150 articles in leading journals on a range of subjects, including viral and bacterial infection and vaccines and holds a number of patents and patent applications.
Alfredo holds a degree in chemistry from the University of Rome, Italy.

10:30 Morning Coffee

11:00 In vitro validation of potential neo-epitopes by MHC based reagents

Sune Justesen has a Ph.D. from the University of Copenhagen. For more than a decade he was responsible for maintaining and developing the probably largest recombinant MHC platform in the laboratory of Dr. Søren Buus. The molecules where used in sensitive peptide binding assays to generate data, that where subsequently used to develop best in class prediction tools for assessing peptide binding to MHC molecules (NetMHC and others). These predictors have proven as invaluable tools in the field of immunology.

The know-how and technology was recently spun out into the company Immunitrack, where Dr. Justesen serves as CSO.

• Affinity vs. Stability based peptide MHC assays, implications on current in silico tools
• What does a neo-epitope look like from the MHC perspective?
• High throughput MHC tetramer production to support personalized cancer vaccination trials

Mads Hald Andersen is vice-director at Center for Cancer Immune Therapy at Copenhagen University Hospital at Herlev as well as professor at Department of Immunology and Microbiology at Copenhagen University. In 2001 he gained his PhD from the Danish Cancer Society, Copenhagen, Denmark, and the Department of Dermatology, Würzburg University, Germany. The same year he co-founded the Tumor Immunology Group at the Danish Cancer Society. He obtained his DScTech in 2006, the same year as he co-founded the Center for Cancer Immune Therapy at Copenhagan University Hospital at Herlev. In 2015 he additionally achieved the DMSc degree from Copenhagen University. Professor Andersen has considerable pharmaceutical experience, and has founded several biotech companies including Survac, Rhovac and most recently IO Biotech Aps. He has been honored with several awards during his career including The Lundbeck Foundation research prize (2012), the Danish Cancer Society Research Award (2006) and the Hallas-Møller Stipend from the Novo Nordisk foundation (2007). He has an extensive publication record, authoring over 150 publications in peer reviewed journals, more than 15 patents as well as several book chapters. His research has been focusing on the characterization of the natural immune responses towards malignant cells. He has identified a number of different T-cell antigens including survivin, the Bcl-2 family and RhoC. Recently, he described circulating T cells that specifically target normal, self-proteins, e.g., IDO, TDO, PD-L1 and Foxp3, expressed by regulatory immune cells and defined these as anti-Tregs.

12:20 Networking Lunch

13:30 Individualised mRNA cancer immunotherapy

Ludwig Heesen studied Biology at the University of Würzburg, Germany from September 2002 to March 2008, after which he obtained his PhD in Genetics, and Post-Doc at the University Hospital Cologne and Institute of Reconstructive Neurobiology, University of Bonn, ending in 2015. Since April 2016 Dr. Heesen has been at BioNTech, where he now works as a Clinical Project Manager.

14:10 Immune modulation as an essential tool for cancer vaccines

• Cancer vaccines require an optimal adjuvant
• The ‘work’ better with correct immune modulation
• Immune modulation can be achieved with IMiDs (Thalidomide analogues) or low dose chemotherapy
• Some agents, such as IMM-101 were developed as cancer vaccines but are actually very powerful immune modulators

Angus Dalgleish, Professor of Oncology, St George's, University of London

14:50 Afternoon Tea

15:20 In vitro assays to accelerate cancer therapy development

Sofie Pattijn, Chief Technology Officer, ImmunXperts

• In vitro assays using primary human cells are a useful tool to screen the functional properties of lead molecules/therapies and to document the mechanism of action
• Development of potency assays
• Functional screening of immune checkpoint inhibitors

Stephanie McArdle is at the head of T-cell vaccine immunotherapy, which is mainly focused on the validation of novel immunotherapeutic targets as well as immune-phenotyping patient’s blood. She is particularly interested in HAGE and PAP antigens as targets and/or biomarkers for cancers. She is also very interested in understanding the role of stress and diet supplement on vaccine outcome. Stephanie supervises many PhD students as director of studies as well as second supervisor and MSc/MRes students. She has recently successfully completed projects contracted by two companies. Academically she has attended the supervisor course as well as the Post-Graduate Certificate for Higher Education (PGCHE) course. Stephanie helps in the teaching of Immunology and Cancer subject areas and regularly reviews original and review type of papers for journals such as Cancer Immunotherapy, Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and Medicinal Chemistry and Cancer Immunity. Stephanie reviews and writes grants and has been part of many European Grants with Prof. Rees. She has established strong collaborations with national and international laboratories and has organised two ELISPOT workshops in collaboration with C.T. Ltd and overseen an International project involving nine laboratories and presented the results of this study at the European Society of cancer and immunotherapy (ESCII) conference held in Athens, Oct. 2008 and has recently organised a Health and Well-Being conference to bring awareness to cancer sufferers as well as healthy people of ways to improve their immune system. This is an area that Stephanie has started to develop over the last few months in collaboration with Prof. Glenn Gibson, Reading University, expert in Prebiotics. Indeed, she is currently assessing the effect of diet supplementation on vaccine-induced immune responses.

16:40 Chairman’s Closing Remarks and Close of Day Two

Alfredo is CEO of Nouscom AG, a biotech company dedicated to the development of next generation immunotherapies to beat cancer (www.nouscom.com).
Alfredo is also CEO of Reithera srl, a Biotech involved in the development of vector-based anti-infectious vaccines.
Alfredo is full Professor of Molecular Biology at the University Federico II, Naples (Italy).
Alfredo was a co-founder of Okairos (recently acquired by GSK) and served as the company’s Chief Scientific Officer, contributing to the preclinical and clinical development of a number of vaccines and monoclonal antibodies against infectious diseases and cancer.
Alfredo’s experience includes the positions of senior director of the Viral Diseases Vaccine program at Istituto di Ricerche di Biologia Molecolare (IRBM), staff scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and project leader at the Sclavo Research Centre in Siena, Italy.
He has also published over 150 articles in leading journals on a range of subjects, including viral and bacterial infection and vaccines and holds a number of patents and patent applications.
Alfredo holds a degree in chemistry from the University of Rome, Italy.

FEATURED SPEAKERS

Agnete B. Fredriksen is Founder and Chief Scientific Officer of Vaccibody AS. She holds a M.Sc., Ph.D. from Institute of Immunology, University of Oslo, Rikshospitalet in Norway where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies. She has co-authored a range of scientific papers and is inventor on several patents with a focus on vaccine development and immunotherapy. She is in charge of preclinical and clinical development of Vaccibody’s cancer vaccine programs.

Dr. Giljohann has served as Exicure’s Chief Executive Officer since November 2013 and been on its board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was Exicure’s Chief Operating Officer and its founding scientist in 2011. From 2011 to June 2012, Dr. Giljohann served as the company’s principal scientist. Prior to that, Dr. Giljohann was the founding scientist of AuraSense, LLC in 2009. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.

Dr. Kandeepan Ganeshalingam received his Medical Degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine, University of London. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK.
Following a 10 year career as a physician in the National Health Service Hospitals, UK, he joined the Oncology product development team at Roche in 2007. In this role he played a significant role in product development with several successful submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the Global Head of Medical and Clinical Drug Safety, where he played a leadership role in clinical development, regulatory submissions and safety risk management. In 2012, he returned to Roche Product Development Medical Affairs as Senior Medical Director, in immunology and was subsequently promoted to Group Medical Director in Oncology, where he led the Global Medical team responsible for multiple Haematology/Oncology products. In this role he was instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies.
In 2016, he joined Merck Sharp Dohme as the Executive Director, Oncology Therapeutic Area Head, European Clinical Development.

Ludwig Heesen studied Biology at the University of Würzburg, Germany from September 2002 to March 2008, after which he obtained his PhD in Genetics, and Post-Doc at the University Hospital Cologne and Institute of Reconstructive Neurobiology, University of Bonn, ending in 2015. Since April 2016 Dr. Heesen has been at BioNTech, where he now works as a Clinical Project Manager.

Mads Hald Andersen is vice-director at Center for Cancer Immune Therapy at Copenhagen University Hospital at Herlev as well as professor at Department of Immunology and Microbiology at Copenhagen University. In 2001 he gained his PhD from the Danish Cancer Society, Copenhagen, Denmark, and the Department of Dermatology, Würzburg University, Germany. The same year he co-founded the Tumor Immunology Group at the Danish Cancer Society. He obtained his DScTech in 2006, the same year as he co-founded the Center for Cancer Immune Therapy at Copenhagan University Hospital at Herlev. In 2015 he additionally achieved the DMSc degree from Copenhagen University. Professor Andersen has considerable pharmaceutical experience, and has founded several biotech companies including Survac, Rhovac and most recently IO Biotech Aps. He has been honored with several awards during his career including The Lundbeck Foundation research prize (2012), the Danish Cancer Society Research Award (2006) and the Hallas-Møller Stipend from the Novo Nordisk foundation (2007). He has an extensive publication record, authoring over 150 publications in peer reviewed journals, more than 15 patents as well as several book chapters. His research has been focusing on the characterization of the natural immune responses towards malignant cells. He has identified a number of different T-cell antigens including survivin, the Bcl-2 family and RhoC. Recently, he described circulating T cells that specifically target normal, self-proteins, e.g., IDO, TDO, PD-L1 and Foxp3, expressed by regulatory immune cells and defined these as anti-Tregs.

Agnete Fredriksen

Co-Founder & CSO, Vaccibody AS

Agnete B. Fredriksen is Founder and Chief Scientific Officer of Vaccibody AS. She holds a M.Sc., Ph.D. from Institute of Immunology, University of Oslo, Rikshospitalet in Norway where she designed and developed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies. She has co-authored a range of scientific papers and is inventor on several patents with a focus on vaccine development and immunotherapy. She is in charge of preclinical and clinical development of Vaccibody’s cancer vaccine programs.

Alfredo Nicosia

CEO, Nouscom AG

Alfredo is CEO of Nouscom AG, a biotech company dedicated to the development of next generation immunotherapies to beat cancer (www.nouscom.com).
Alfredo is also CEO of Reithera srl, a Biotech involved in the development of vector-based anti-infectious vaccines.
Alfredo is full Professor of Molecular Biology at the University Federico II, Naples (Italy).
Alfredo was a co-founder of Okairos (recently acquired by GSK) and served as the company’s Chief Scientific Officer, contributing to the preclinical and clinical development of a number of vaccines and monoclonal antibodies against infectious diseases and cancer.
Alfredo’s experience includes the positions of senior director of the Viral Diseases Vaccine program at Istituto di Ricerche di Biologia Molecolare (IRBM), staff scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and project leader at the Sclavo Research Centre in Siena, Italy.
He has also published over 150 articles in leading journals on a range of subjects, including viral and bacterial infection and vaccines and holds a number of patents and patent applications.
Alfredo holds a degree in chemistry from the University of Rome, Italy.

Amotz Shemi

CEO, Silenseed

Angus Dalgleish

Professor of Oncology, St George's, University of London

Antoine Toubert

Head, Alloimmunity, Autoimmunity, Transplantation, INSERM

David Giljohann

CEO, Exicure Inc.

Dr. Giljohann has served as Exicure’s Chief Executive Officer since November 2013 and been on its board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was Exicure’s Chief Operating Officer and its founding scientist in 2011. From 2011 to June 2012, Dr. Giljohann served as the company’s principal scientist. Prior to that, Dr. Giljohann was the founding scientist of AuraSense, LLC in 2009. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and spherical nucleic acid constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.

Eric Tartour

Farzin Farzaneh

Professor of Molecular Medicine, Kings College London

Farzin joined King’s College London as a lecturer in Molecular Genetics in 1985, founded the Molecular Genetics Unit in 1986 and was appointed the founding Head of the Department of Molecular Genetics in 1993. Farzin has published over 200 scientific papers and two edited books on the Functional Analysis of the Genome and Cancer Gene Therapy. He leads an active research group with a current funding of over £2M per annum from Leukaemia Lymphoma Research (now Bloodwise), CRUK, National Institute for Health Research, UK Research Councils, as well as the biotech and pharmaceutical industry.

Jonathan Zalevsky

Kandeepan Ganeshalingam

Dr. Kandeepan Ganeshalingam received his Medical Degree from the University of Aberdeen and a Master of Science Degree from the Imperial College School of Medicine, University of London. He was also the Faraday Research fellow at the National Heart and Lung Institute, UK.
Following a 10 year career as a physician in the National Health Service Hospitals, UK, he joined the Oncology product development team at Roche in 2007. In this role he played a significant role in product development with several successful submissions to EMA and FDA. In 2010, he moved to Vifor Pharma, Switzerland to become the Global Head of Medical and Clinical Drug Safety, where he played a leadership role in clinical development, regulatory submissions and safety risk management. In 2012, he returned to Roche Product Development Medical Affairs as Senior Medical Director, in immunology and was subsequently promoted to Group Medical Director in Oncology, where he led the Global Medical team responsible for multiple Haematology/Oncology products. In this role he was instrumental in building clinical trial collaborations with academic groups and external pharmaceutical companies.
In 2016, he joined Merck Sharp Dohme as the Executive Director, Oncology Therapeutic Area Head, European Clinical Development.

Ludwig Heesen

Project Manager, BioNTech AG

Ludwig Heesen studied Biology at the University of Würzburg, Germany from September 2002 to March 2008, after which he obtained his PhD in Genetics, and Post-Doc at the University Hospital Cologne and Institute of Reconstructive Neurobiology, University of Bonn, ending in 2015. Since April 2016 Dr. Heesen has been at BioNTech, where he now works as a Clinical Project Manager.

Mads Hald Andersen

Vice-Director, Professor, Co-Founder, ccit-denmark

Mads Hald Andersen is vice-director at Center for Cancer Immune Therapy at Copenhagen University Hospital at Herlev as well as professor at Department of Immunology and Microbiology at Copenhagen University. In 2001 he gained his PhD from the Danish Cancer Society, Copenhagen, Denmark, and the Department of Dermatology, Würzburg University, Germany. The same year he co-founded the Tumor Immunology Group at the Danish Cancer Society. He obtained his DScTech in 2006, the same year as he co-founded the Center for Cancer Immune Therapy at Copenhagan University Hospital at Herlev. In 2015 he additionally achieved the DMSc degree from Copenhagen University. Professor Andersen has considerable pharmaceutical experience, and has founded several biotech companies including Survac, Rhovac and most recently IO Biotech Aps. He has been honored with several awards during his career including The Lundbeck Foundation research prize (2012), the Danish Cancer Society Research Award (2006) and the Hallas-Møller Stipend from the Novo Nordisk foundation (2007). He has an extensive publication record, authoring over 150 publications in peer reviewed journals, more than 15 patents as well as several book chapters. His research has been focusing on the characterization of the natural immune responses towards malignant cells. He has identified a number of different T-cell antigens including survivin, the Bcl-2 family and RhoC. Recently, he described circulating T cells that specifically target normal, self-proteins, e.g., IDO, TDO, PD-L1 and Foxp3, expressed by regulatory immune cells and defined these as anti-Tregs.

Rose-Ann Padua

Director of Research, INSERM

Sharam Kordasti

Senior Lecturer, Kings College London

Sofie Pattijn

Chief Technology Officer, ImmunXperts

Stephanie McArdle

Senior Research Scientist, Nottingham Trent University

Stephanie McArdle is at the head of T-cell vaccine immunotherapy, which is mainly focused on the validation of novel immunotherapeutic targets as well as immune-phenotyping patient’s blood. She is particularly interested in HAGE and PAP antigens as targets and/or biomarkers for cancers. She is also very interested in understanding the role of stress and diet supplement on vaccine outcome. Stephanie supervises many PhD students as director of studies as well as second supervisor and MSc/MRes students. She has recently successfully completed projects contracted by two companies. Academically she has attended the supervisor course as well as the Post-Graduate Certificate for Higher Education (PGCHE) course. Stephanie helps in the teaching of Immunology and Cancer subject areas and regularly reviews original and review type of papers for journals such as Cancer Immunotherapy, Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and Medicinal Chemistry and Cancer Immunity. Stephanie reviews and writes grants and has been part of many European Grants with Prof. Rees. She has established strong collaborations with national and international laboratories and has organised two ELISPOT workshops in collaboration with C.T. Ltd and overseen an International project involving nine laboratories and presented the results of this study at the European Society of cancer and immunotherapy (ESCII) conference held in Athens, Oct. 2008 and has recently organised a Health and Well-Being conference to bring awareness to cancer sufferers as well as healthy people of ways to improve their immune system. This is an area that Stephanie has started to develop over the last few months in collaboration with Prof. Glenn Gibson, Reading University, expert in Prebiotics. Indeed, she is currently assessing the effect of diet supplementation on vaccine-induced immune responses.

Sune Justesen

CSO, Immunitrack Aps

Sune Justesen has a Ph.D. from the University of Copenhagen. For more than a decade he was responsible for maintaining and developing the probably largest recombinant MHC platform in the laboratory of Dr. Søren Buus. The molecules where used in sensitive peptide binding assays to generate data, that where subsequently used to develop best in class prediction tools for assessing peptide binding to MHC molecules (NetMHC and others). These predictors have proven as invaluable tools in the field of immunology.

The know-how and technology was recently spun out into the company Immunitrack, where Dr. Justesen serves as CSO.

Zahra Jawad

Group Leader in Discovery Technology, Agenus

Zwi Berneman

Professor of Haematology, University Of Antwerp

Sponsors and Exhibitors

"The Company (NWBio) has received some shareholder inquiries about whether the Company will be presenting at the SMi conference in London on September 27-28, 2017. While anticipating the disclosure of interim blinded data from NWBio’s Phase III trial of DCVax®-L for Glioblastoma, NWBio will not be presenting at this year’s SMi conference.”

NWBio is developing DCVax® dendritic cell-based therapeutic vaccines. The Company’s DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and Phase II trials in combination with checkpoint inhibitor drugs are planned. The Company’s DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers; various Phase II trials are planned.

View detailsTailored Clinical Research SolutionsSponsors and Exhibitorshttp://www.tcr-solutions.com/Tailored Clinical Research Solutions (www.tcr-solutions.com) recognise that Cancer Vaccine studies are among the most complex projects that a CRO will undertake.
We know this because we are experts in oncology clinical development. That is why we will never ask a CRA with less than 7 years experience to work on your study. And why we ensure that our sponsors work with the very best oncology sites from our tried and tested global network.
Whether you are seeking full support for your clinical development programme or just for one part of a study, TCRS offers flexibility, momentum and value.

Official Publication

View detailsInt. J. of Immunological StudiesOfficial Publicationhttp://www.inderscience.com/ijisIJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.

View detailsInternational Journal of Behavioural and Healthcare ResearchOfficial Publicationhttp://www.inderscience.com/ijbhrIJBHR addresses a broad range of original experimental and theoretical papers that deal with behavioural and healthcare concerns. It welcomes high-quality papers from scientists in academic and non-academic organisations as well as business and government worldwide. IJBHR is sponsored by the Business and Economics Society International and the Frontiers in Immunology Research Network.

View detailsInternational Journal of Cognitive BiometricsOfficial Publicationhttp://www.inderscience.com/ijcbCognitive biometrics acquires information from users through collection of one or more biosignals. This relies on the presentation of one or more external or imagined stimuli. The subsequent response(s) are acquired and used for verification and authentication. IJCB addresses all aspects of cognitive biometrics, which aims to extract a unique signature from the user based on the cognitive, affective and conative state of the individual, either alone or more typically in various multi-modal combinations involving conventional and soft biometrics.

View detailsInternational Journal of Computational Biology and Drug DesignOfficial Publicationhttp://www.inderscience.com/ijcbddIJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.

View detailsInternational Journal of Medical Engineering and InformaticsOfficial Publicationhttp://www.inderscience.com/ijmeiIJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.

The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

View detailsBentham ScienceSupportershttp://www.benthamscience.com/Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com

View detailsBioChem Adda Supportershttps://www.biochemadda.com/BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

View detailsBiocompareSupportershttp://www.biocompare.comBiocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.

View detailsBioPharm InsightSupportershttp://www.biopharminsight.com
BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

View detailsBiosaveSupportershttp://www.Biosave.comBiosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

View detailsCLocateSupportershttp://www.clocate.comClocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's website and more...

View detailsCopybook - PharmaceuticalSupportershttp://www.copybook.com/pharmaceuticalCopybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions?
SIGN UP FOR FREE today!
Copybook – Your Global Business Network

View detailsDrug Development TechnologySupportershttp://www.drugdevelopment-technology.comDrugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval.
Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.

View detailsDrug Discovery TodaySupportershttp://www.drugdiscoverytoday.com/Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.

View detailsDrug Target ReviewSupportershttp://www.drugtargetreview.comDrug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.

View detailsEIN PresswireSupportershttp://www.einpresswire.com/freeEIN Presswire has a distribution "foot-print" that includes millions of users of our EIN Newsdesk media monitoring services. We also maintain one of the world's leading media directories providing us with up-to-date contacts for media in every country and U.S. state. Further distribution is achieved via RSS, email, partner websites, and social media. We are both a destination (EIN Newsdesk) and a distributor (EIN Presswire) for news. In one place you can distribute your news to the targeted audiences you select and monitor news on that topic published by thousands of worldwide sources. For more information or to try us FREE, please visit www.einpresswire.com/free

View detailsFarmavitaSupportershttp://www.farmavita.net/Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.

View detailsGate2BiotechSupportershttp://www.gate2biotech.comGate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

View detailsGBISupportershttp://www.gbihealth.com/GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.

View detailsInderscience PublishersSupportershttp://www.inderscience.comInderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.

View detailsInternational Pharmaceutical IndustrySupportershttp://www.ipimediaworld.com IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.

View detailsLabsaveSupportershttp://www.labsave.comLabsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

View detailsMednousSupportershttp://www.MedNous.comMedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

View detailsPharmaceutical TechnologySupportershttp://www.pharmaceutical-technology.comPharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

View detailsPharmaceutical-TechSupportershttp://www.pharmaceutical-tech.comIn the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers.
Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics. With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.

View detailsPharmacircleSupportershttp://www.pharmacircle.comPharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….

View detailsPharmalicensingSupportershttp://www.pharmalicensing.comPharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world.
Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

View detailspharmaphorumSupportershttp://www.pharmaphorum.compharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

View detailsPharmavisionSupportershttp://www.pharmavision.co.ukPharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.

View detailsPharmiwebSupportershttp://www.pharmiweb.comEstablished in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.

View detailsPMRSupportershttp://www.pmrcorporate.comPMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.

View detailsSamedanSupportershttp://www.samedanltd.com/magazine/13.International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.

View detailsSciDoc PublishersSupportershttp://www.scidoc.orgSciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.

View detailsSelect ScienceSupportershttp://www.selectscience.net/SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

View detailsSwiss Biotech AssociationSupportershttp://www.swissbiotech.org/The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

View detailsTechnology NetworksSupportershttp://go.technologynetworks.com/subscribe-to-newslettersFounded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

Q&A WITH NEKTAR: How accessible will fully-personalised cancer treatments will become?

Q&A WITH KINGS COLLEGE LONDON: ARE WE CLOSER TO ACHIEVING SUSTAINED ANTITUMOR RESPONE?

Sponsors and Exhibitors

Northwest Biotherapeutics

"The Company (NWBio) has received some shareholder inquiries about whether the Company will be presenting at the SMi conference in London on September 27-28, 2017. While anticipating the disclosure of interim blinded data from NWBio’s Phase III trial of DCVax®-L for Glioblastoma, NWBio will not be presenting at this year’s SMi conference.”

NWBio is developing DCVax® dendritic cell-based therapeutic vaccines. The Company’s DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and Phase II trials in combination with checkpoint inhibitor drugs are planned. The Company’s DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers; various Phase II trials are planned.

Tailored Clinical Research Solutions

Tailored Clinical Research Solutions (www.tcr-solutions.com) recognise that Cancer Vaccine studies are among the most complex projects that a CRO will undertake.
We know this because we are experts in oncology clinical development. That is why we will never ask a CRA with less than 7 years experience to work on your study. And why we ensure that our sponsors work with the very best oncology sites from our tried and tested global network.
Whether you are seeking full support for your clinical development programme or just for one part of a study, TCRS offers flexibility, momentum and value.

Media Partners

International Journal of Behavioural and Healthcare Research

IJBHR addresses a broad range of original experimental and theoretical papers that deal with behavioural and healthcare concerns. It welcomes high-quality papers from scientists in academic and non-academic organisations as well as business and government worldwide. IJBHR is sponsored by the Business and Economics Society International and the Frontiers in Immunology Research Network.

International Journal of Cognitive Biometrics

Cognitive biometrics acquires information from users through collection of one or more biosignals. This relies on the presentation of one or more external or imagined stimuli. The subsequent response(s) are acquired and used for verification and authentication. IJCB addresses all aspects of cognitive biometrics, which aims to extract a unique signature from the user based on the cognitive, affective and conative state of the individual, either alone or more typically in various multi-modal combinations involving conventional and soft biometrics.

International Journal of Medical Engineering and Informatics

IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.

Int. J. of Immunological Studies

IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.

International Journal of Computational Biology and Drug Design

IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.

Media Partners

International Pharmaceutical Industry

IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.

Pharmaceutical-Tech

In the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers.
Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics. With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.

Select Science

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.

pharmaphorum

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com

The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

Bentham Science

Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com

Drug Target Review

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.

PMR

PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.

Samedan

International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.

Farmavita

Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.

Biocompare

Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.

EIN Presswire

EIN Presswire has a distribution "foot-print" that includes millions of users of our EIN Newsdesk media monitoring services. We also maintain one of the world's leading media directories providing us with up-to-date contacts for media in every country and U.S. state. Further distribution is achieved via RSS, email, partner websites, and social media. We are both a destination (EIN Newsdesk) and a distributor (EIN Presswire) for news. In one place you can distribute your news to the targeted audiences you select and monitor news on that topic published by thousands of worldwide sources. For more information or to try us FREE, please visit www.einpresswire.com/free

Pharmiweb

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.

Swiss Biotech Association

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.

GBI

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.

Technology Networks

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

Inderscience Publishers

Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.

Copybook - Pharmaceutical

Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions?
SIGN UP FOR FREE today!
Copybook – Your Global Business Network

Biosave

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.

Drug Development Technology

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval.
Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.

CLocate

Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's website and more...

Drug Discovery Today

Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.

Mednous

MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

Gate2Biotech

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

Pharmalicensing

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.
Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world.
Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

BioPharm Insight

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.

Pharmaceutical Technology

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.

BioChem Adda

BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

SciDoc Publishers

SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.

Labsave

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

Cookie Policy

From May 2011 a new privacy law came into effect across the EU. The law requires
that websites ask visitors for consent to use most web cookies. We use cookies to
ensure you get the best experience on our website –Tick here to accept cookie use
Details of our cookie use may be found here.

WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy,
which maintains that in order to be effective, learning should be organised and
structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional
competence’

CPD is a common requirement of individual membership with professional bodies and
Institutes. Increasingly, employers also expect their staff to undertake regular
CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do
not become obsolete, and allows for best practice and professional standards to
be upheld.

CPD can be undertaken through a variety of learning activities including instructor
led training courses, seminars and conferences, e:learning modules or structured
reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with
a collective membership of circa 4 million professionals, and they all expect their
members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked
to a licence to practice, for others it’s obligatory. By ensuring that their members
undertake CPD, the professional bodies seek to ensure that professional standards,
legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide
online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’
or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve
within a given time period. These schemes can also use different ‘currencies’ such
as points, merits, units or credits, where an individual must accumulate the number
required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of
learning.

‘Output’ based schemes are learner centred. They require individuals to set learning
goals that align to professional competencies, or personal development objectives.
These schemes also list different ways to achieve the learning goals e.g. training
courses, seminars or e:learning, which enables an individual to complete their CPD
through their preferred mode of learning.

As a formal provider of CPD certified activities, SMI Group can provide an indication
of the learning benefit gained and the typical completion. However, it is ultimately
the responsibility of the delegate to evaluate their learning, and record it correctly
in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces
and looking to the UK to benchmark educational standards. The undertaking of CPD
is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk